ozanimod
Sign in to saveAlso known as RPC-1063, RPC1063
Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.
~12 min read
Encyclopedic overview
15 sectionsContents
- Medical uses
- Pharmacology
- Potency and selectivity
- Mechanism of action, pharmacodynamics
- Pharmacokinetics
- History
- Clinical trials
- Touchstone
- Radiance
- Sunbeam
- Society and culture
- Commercial
- Research
- References
- External links
{{Infobox drug | image = Ozanimod.svg | image_class = skin-invert-image | width = 285 | alt = | image2 = Ozanimod ball-and-stick model.png | image_class2 = bg-transparent | width2 = | alt2 = | caption =
| pronounce = | tradename = Zeposia | Drugs.com = | MedlinePlus = a620029 | licence_CA = | licence_EU = yes | DailyMedID = Ozanimod | licence_US = | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L04 | ATC_suffix = AE02 | ATC_supplemental =
Excerpted from Wikipedia’s “ozanimod” article, available under the CC BY-SA 4.0 licence.